Kane Biotech Inc. (CVE:KNE – Get Free Report) shares were up 20% during mid-day trading on Friday . The company traded as high as C$0.03 and last traded at C$0.03. 102,100 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 175,952 shares. The stock had previously closed at C$0.03.
Kane Biotech Trading Up 20.0%
The company has a quick ratio of 0.39, a current ratio of 0.45 and a debt-to-equity ratio of -135.17. The firm has a market cap of C$6.15 million, a price-to-earnings ratio of -3.00 and a beta of 1.05. The company has a 50-day moving average price of C$0.03 and a 200 day moving average price of C$0.03.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
See Also
- Five stocks we like better than Kane Biotech
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
